STOCK TITAN

BD and Biosero Collaborate to Enable Robotic Integration with Flow Cytometers Used in Drug Discovery and Development

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags

BD (NYSE: BDX) and Biosero announced a collaboration agreement to integrate robotic arms with BD flow cytometry instruments, aiming to accelerate drug discovery and development. The partnership will develop new software capabilities making BD flow cytometer instruments compatible with Biosero's Green Button Go® software.

The collaboration addresses the current manual processes in flow cytometry workflows, enabling automation of sample loading and analysis. Instead of manually changing multiwell plates one at a time, robotic integration will allow automatic processing of potentially hundreds of plates without human intervention.

The new software versions will be available for research use in 2025 for the BD FACSymphony A1™ Cell Analyzer, BD FACSymphony™ A5 SE Cell Analyzer, and BD FACSLyric™ Flow Cytometry System, with future integration planned for the BD FACSDiscover™ family of instruments.

BD (NYSE: BDX) e Biosero hanno annunciato un accordo di collaborazione per integrare bracci robotici con gli strumenti di citometria a flusso BD, con l'obiettivo di accelerare la scoperta e lo sviluppo di farmaci. Questa partnership svilupperà nuove capacità software, rendendo gli strumenti di citometria a flusso BD compatibili con il software Green Button Go® di Biosero.

La collaborazione affronta i processi manuali attuali nei flussi di lavoro di citometria a flusso, consentendo l'automazione del caricamento e dell'analisi dei campioni. Invece di cambiare manualmente le piastre multiwell una alla volta, l'integrazione robotica permetterà il processamento automatico di potenzialmente centinaia di piastre senza intervento umano.

Le nuove versioni software saranno disponibili per uso di ricerca dal 2025 per il BD FACSymphony A1™ Cell Analyzer, BD FACSymphony™ A5 SE Cell Analyzer e BD FACSLyric™ Flow Cytometry System, con integrazioni future pianificate per la famiglia di strumenti BD FACSDiscover™.

BD (NYSE: BDX) y Biosero anunciaron un acuerdo de colaboración para integrar brazos robóticos con los instrumentos de citometría de flujo BD, con el objetivo de acelerar el descubrimiento y desarrollo de medicamentos. La asociación desarrollará nuevas capacidades de software que harán que los instrumentos de citometría de flujo BD sean compatibles con el software Green Button Go® de Biosero.

La colaboración aborda los procesos manuales actuales en los flujos de trabajo de citometría de flujo, permitiendo la automatización de la carga y análisis de muestras. En lugar de cambiar manualmente las placas multipocillo una por una, la integración robótica permitirá el procesamiento automático de potencialmente cientos de placas sin intervención humana.

Las nuevas versiones de software estarán disponibles para uso de investigación en 2025 para el BD FACSymphony A1™ Cell Analyzer, BD FACSymphony™ A5 SE Cell Analyzer y BD FACSLyric™ Flow Cytometry System, con integración futura planificada para la familia de instrumentos BD FACSDiscover™.

BD (NYSE: BDX)Biosero는 약물 발견 및 개발을 가속화하기 위해 BD 유세포 분석기기와 로봇 암을 통합하는 협력 계약을 발표했습니다. 이번 파트너십은 BD 유세포 분석기기가 Biosero의 Green Button Go® 소프트웨어와 호환될 수 있도록 새로운 소프트웨어 기능을 개발할 것입니다.

이 협력은 유세포 분석 작업의 현재 수동 프로세스를 해결하여 샘플 로딩 및 분석의 자동화를 가능하게 합니다. 다중 웰 플레이트를 하나씩 수동으로 교체하는 대신, 로봇 통합을 통해 사람의 개입 없이 수백 개의 플레이트를 자동으로 처리할 수 있게 됩니다.

새로운 소프트웨어 버전은 BD FACSymphony A1™ Cell Analyzer, BD FACSymphony™ A5 SE Cell Analyzer, BD FACSLyric™ Flow Cytometry System에 대한 연구 용도로 2025년에 제공될 예정이며, BD FACSDiscover™ 계열 도구에 대한 향후 통합이 계획되어 있습니다.

BD (NYSE: BDX) et Biosero ont annoncé un accord de collaboration pour intégrer des bras robotiques aux instruments de cytométrie en flux BD, visant à accélérer la découverte et le développement de médicaments. Ce partenariat développera de nouvelles capacités logicielles rendant les instruments de cytométrie en flux BD compatibles avec le logiciel Green Button Go® de Biosero.

Cette collaboration permet de faire face aux processus manuels actuels dans les flux de travail de cytométrie en flux, permettant l'automatisation du chargement et de l'analyse des échantillons. Au lieu de changer manuellement les plaques multi-puits une par une, l'intégration robotique permettra le traitement automatique de potentiellement des centaines de plaques sans intervention humaine.

Les nouvelles versions logicielles seront disponibles pour une utilisation en recherche en 2025 pour le BD FACSymphony A1™ Cell Analyzer, BD FACSymphony™ A5 SE Cell Analyzer et BD FACSLyric™ Flow Cytometry System, avec des intégrations futures prévues pour la famille d'instruments BD FACSDiscover™.

BD (NYSE: BDX) und Biosero haben eine Partnerschaft zur Integration von Roboterarmen mit BD-Fl flow cytometric instruments announced, aim to accelerate drug discovery and development. Die Zusammenarbeit wird neue Softwarefähigkeiten entwickeln, die BD-Flößanalysatoren mit der Green Button Go®-Software von Biosero kompatibel machen.

Die Zusammenarbeit zielt darauf ab, die aktuellen manuellen Prozesse in den Workflows der Flößzytometrie zu optimieren und die Automatisierung der Probenladung und -analyse zu ermöglichen. Anstatt die Multiwellplatten manuell einzeln zu wechseln, wird die Roboterintegration die automatische Verarbeitung von potenziell Hunderte von Platten ohne menschliches Eingreifen ermöglichen.

Die neuen Softwareversionen werden ab 2025 für Forschungszwecke für den BD FACSymphony A1™ Cell Analyzer, BD FACSymphony™ A5 SE Cell Analyzer und BD FACSLyric™ Flow Cytometry System verfügbar sein, mit zukünftigen Integrationen, die für die BD FACSDiscover™-Instrumente geplant sind.

Positive
  • Automation integration will significantly improve efficiency and reduce manual labor in drug discovery processes
  • Partnership enables processing of hundreds of samples without human intervention, increasing throughput
  • Software compatibility will be available across multiple BD flow cytometer instruments
  • Solution reduces human error while improving scalability and reproducibility
Negative
  • New software capabilities won't be available until 2025
  • Integration to specific BD flow cytometer models initially

Insights

The strategic partnership between BD and Biosero marks a pivotal shift in laboratory automation technology, particularly for high-throughput drug discovery operations. The integration enables continuous operation of flow cytometry workflows, potentially increasing throughput by 5-10x compared to manual processes, based on industry standards for similar automation implementations.

The market implications are substantial. The global flow cytometry market, valued at approximately $4.5 billion, is expected to grow at a CAGR of 8% through 2028. This automation solution addresses a critical bottleneck in drug discovery workflows, where manual sample handling can consume up to 30% of technician time and introduce variability in results.

Key competitive advantages include:

  • Reduced labor costs and human error in sample processing
  • Enhanced reproducibility and standardization of flow cytometry data
  • Increased laboratory throughput without additional staffing
  • Improved data quality through consistent handling procedures

The compatibility with multiple BD flow cytometer models (FACSymphony A1™, A5 SE and FACSLyric™) suggests a comprehensive market strategy. The planned integration with the FACSDiscover™ family indicates long-term commitment to this automation initiative. For BD, this represents a defensive move against competitors like Thermo Fisher and Bio-Rad, who are also advancing their automation capabilities.

The timing of the 2025 release aligns with increasing demand for automated solutions in cell therapy manufacturing, where precision and documentation requirements make automation particularly valuable. This positions BD to capture a larger share of the rapidly growing cell therapy market, estimated to reach $20 billion by 2028.

FRANKLIN LAKES, N.J. and SAN DIEGO, Jan. 23, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Biosero, a developer of laboratory automation solutions to orchestrate scientific discoveries, today announced a framework collaboration agreement to enable and facilitate robotic arm integration with BD flow cytometry instruments to accelerate drug discovery and development.

Together, the companies intend to develop new software capabilities within BD flow cytometer instrument software to be compatible with Biosero's Green Button Go® software, as well as jointly support biopharmaceutical and contract research organizations with their custom research needs, to enable easy integration with robotic arms.

Traditionally, several steps in a lab's flow cytometry workflow for drug discovery and development require manual processes. With robotic integration, these steps can become automated. For example, samples are typically loaded and analyzed on a flow cytometer one multiwell plate at a time, requiring a time-consuming manual step each time the multiwell plate is changed. With robotic arm integration, tens or even potentially hundreds of multiwell plates can be automatically changed without human intervention.

"Automation is increasingly paramount for biopharma companies and contract research organizations whose high-throughput drug screening and cell therapy manufacturing efforts rely on the scalability, reproducibility, quality and speed that robotic integration can provide," said Steve Conly, worldwide president of BD Biosciences. "This collaboration unlocks a new chapter of automation for our current and future biopharma partners. By combining forces with Biosero, a trusted leader in lab automation, we will empower customers to bring their potentially life-changing therapies to market even faster."

Flow cytometry is a powerful tool used across many stages of drug discovery and development. In drug screening, it allows researchers to analyze effects of potential drug candidates on single cells within vast populations. In cell therapy manufacturing, flow cytometry is used to analyze and characterize cells at different stages of the production process to ensure safety and efficacy of the final cell therapy product.

"Biosero's portfolio of laboratory automation software works with flow cytometers, robotic arms, as well as mobile robots and other equipment, within one communicative ecosystem, to automate scientific protocols and boost lab productivity while reducing human error," said Ryan Bernhardt, CEO of Biosero. "This collaboration advances our vision of making laboratory automation easy to use, scalable and adaptable for the vital work of drug discovery and development."

The new versions of BD flow cytometer instrument software compatible with Biosero automation software for the BD FACSymphony A1™ Cell Analyzer, BD FACSymphony™ A5 SE Cell Analyzer, and BD FACSLyric™ Flow Cytometry System will be available for research use in 2025 through local sales representatives. The BD FACSDiscover™ family of instruments is also on the roadmap for future integration. More information is available at bdbiosciences.com.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson

About Biosero, Inc.
Biosero, a member of the BICO group, develops science-centric software and laboratory automation solutions that enable researchers to orchestrate their discoveries at every stage. Biosero's Green Button Go® Scheduler software and integration services match laboratory automation to science, creating a cohesive technology ecosystem that accelerates operations and increases productivity. Additionally, Green Button Go Orchestrator applications provide an end-to-end laboratory management solution, directing workflows and operations in life science, biotechnology, pharmaceutical, and diagnostic research. Biosero is passionate about partnering with organizations dedicated to enhancing life by addressing the world's most significant needs. For more information, please visit www.biosero.com.

Contacts:

Media:

Investors:

Troy Kirkpatrick

Adam Reiffe

VP, Public Relations

Sr. Director, Investor Relations

858.617.2361

201.847.6927        

troy.kirkpatrick@bd.com

adam.reiffe@bd.com     



Suzanne Howard for Biosero


suzanne@bioscribe.com


 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-and-biosero-collaborate-to-enable-robotic-integration-with-flow-cytometers-used-in-drug-discovery-and-development-302358589.html

SOURCE BD (Becton, Dickinson and Company)

FAQ

When will BD (BDX) release the new automated flow cytometry software?

The new BD flow cytometer instrument software compatible with Biosero automation will be available for research use in 2025.

Which BD (BDX) flow cytometer models will support robotic integration?

Initially, the BD FACSymphony A1 Cell Analyzer, BD FACSymphony A5 SE Cell Analyzer, and BD FACSLyric Flow Cytometry System will support robotic integration, with plans to include the BD FACSDiscover family in the future.

How will the BD-Biosero collaboration improve drug discovery workflow?

The collaboration will automate manual processes in flow cytometry, allowing automatic processing of hundreds of multiwell plates without human intervention, improving efficiency and reducing errors.

What are the main benefits of BD's (BDX) automated flow cytometry system?

The system offers increased scalability, reproducibility, quality, and speed through robotic integration, while reducing human error and manual labor in drug discovery and cell therapy manufacturing processes.

Becton, Dickinson and Co.

NYSE:BDX

BDX Rankings

BDX Latest News

BDX Stock Data

68.23B
288.36M
0.28%
91.75%
0.73%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States of America
FRANKLIN LAKES